Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2019 June;71(3) > Minerva Ginecologica 2019 June;71(3):182-90

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Minerva Ginecologica 2019 June;71(3):182-90

DOI: 10.23736/S0026-4784.19.04249-7

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study

John SYRIOS, Charalambos KOUROUSSIS, Athanasios KOTSAKIS, Nikolaos KENTEPOZIDIS, Emmanouil KONTOPODIS, Kostas KALBAKIS, Nikolaos VARDAKIS, Dora HATZIDAKI, Aris POLYZOS, Vassilis GEORGOULIAS , on behalf of the GU Working Group of the Hellenic Oncology Research Group (HORG)

Hellenic Oncology Research Group (HORG), Athens, Greece



BACKGROUND: Evaluation of safety of the weekly intravenous gemcitabine/topotecan combination as salvage treatment in patients with recurrent epithelial ovarian cancer.
METHODS: Twenty-four women with histologically-proven relapsed ovarian cancer (ROC) were enrolled in the study. Topotecan (1.75 mg/m2 IV) along with escalated doses of gemcitabine (starting dose 700 mg/m2 with increments of 100 mg/m2) were administered on days 1, 8, and 15 every 28 days. The maximum tolerated dose (MTD) and the dose-limiting toxicity of the combination were evaluated at the first cycle.
RESULTS: Twenty-four ROC patients were enrolled in six dose-levels. Most patients had high-grade serous metastatic ovarian cancer (41.7%) and performance status score of 0-1 (95.8%). For 12 patients (50%) treatment was 2nd line and for 12 >2nd line. Eighty-eight cycles were administered with a median of three cycles per patient. The MTD was not reached and grade 3-4 (3.4% and 2.3% of cycles, respectively) neutropenia and grade 4 (3.4% of cycles) thrombocytopenia were the main adverse events. There was no case of febrile neutropenia. Non-hematologic toxicity was mild with grade 2 fatigue being the most frequent complain. The recommended MTD doses of the combination were topotecan 1.75 mg/m2 and gemcitabine 1200 mg/m2 on days 1, 8, and 15 every 28 days. Two complete (8.3%) and three (12.5%) partial responses were achieved (ORR: 20.8%).
CONCLUSIONS: The weekly administration of gemcitabine/topotecan regimen in patients with pretreated metastatic ovarian cancer is an active chemotherapy combination, even in heavily pretreated patients, with a manageable toxicity profile which merits further investigation.


KEY WORDS: Topotecan; Gemcitabine; Ovarian neoplasms; Local cancer recurrence

top of page